Sinovac reports Phase III data for varicella vaccine

In September, Sinovac Biotech Ltd. (NASDAQ:SVA) reported top-line data from a Phase III trial in about 6,000 healthy children aged 1-12 showing that its Varicella vaccine prevented varicella zoster virus (VZV) infection in 87.1% of patients. The double-blind, placebo-controlled Chinese trial's primary endpoints are evaluating the incidence of varicella and the vaccine's protection rate. Secondary endpoints include safety, seroconversion rates and pharmacokinetics...